Leaf Science

JULY 23, 2019

In the UK, cannabis was legalized for medicinal purposes in 2018 which saw patients of epilepsy and multiple sclerosis able to access pharmaceutical cannabis derivatives such as Sativex and Epidiolex. We shall look into what these benefits may be and what the science do we have that backs this up. Medicinal cannabis in the western world.

Strains 74

Strains Cannabinoids Epilepsy THC 74

Puff Puff Post

MARCH 2, 2020

Source: New Frontier Data). · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. SOURCE Khiron Life Sciences Corp.

Extraction 52

Extraction THC Chronic Pain Cultivation 52

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Media: media@mymd.com. Chief Scientific Officer.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Puff Puff Post

MARCH 2, 2020

Source: New Frontier Data). · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. SOURCE Khiron Life Sciences Corp.

Extraction 40

Extraction THC Chronic Pain Cultivation 40

CannaMD

AUGUST 19, 2020

The CDC notes that individuals of all ages may contract COVID-19; however, the risk of death is significantly higher for older populations and those with underlying health conditions. Our initial data suggest that some C. Note: Study extracts were applied via media. The Coronavirus and Cytokine Storms.

Research and Development 141

Research and Development Marijuana Extraction Terpenes 141

Cannabis Law Report

NOVEMBER 26, 2019

Many unanswered questions and data gaps about CBD toxicity exist, and some of the available data raise serious concerns about potential harm from CBD. The FDA has not approved any CBD products other than one prescription human drug product to treat rare, severe forms of epilepsy.

Safety 64

Safety Food CBD Oil 64

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g.,

CBD 40

CBD Research and Development Safety Therapy 40

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 20, 2022

The transaction is expected to close in the second or third quarter of 2022, subject to customary closing conditions, including the receipt of regulatory approvals and approval by SPKB’s shareholders. Media and Investor Contacts For Eleusis: Alex Speiser, Corporate Development Director. Email: alexander.speiser@eleusisltd.com.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Background. Bonini et al.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JULY 12, 2019

As reported in the Guardian, Analytical Cannabis emphasises the importance of this for those suffering from conditions such as chronic pain, epilepsy and neurological and psychiatric disorders who have long been seeking access to what they hope is a transformative medicine.

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

Cannabis Law Report

SEPTEMBER 1, 2022

AUSTIN, Texas, August 31, 2022 –( BUSINESS WIRE )–As Pain Awareness Month begins, Texas Original is calling on Texas’ legislature to add chronic pain as a qualifying condition to the state’s Compassionate Use Program (CUP). “The data is clear. For Media Inquiries Only: Callie Neatherlin. It’s not a maybe.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

Cannabis Law Report

AUGUST 31, 2022

AUSTIN, Texas–(BUSINESS WIRE)–As Pain Awareness Month begins, Texas Original is calling on Texas’ legislature to add chronic pain as a qualifying condition to the state’s Compassionate Use Program (CUP). Chronic pain is one of the most prevalent and provable conditions that medical cannabis can positively impact.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

StrainConnect

FEBRUARY 8, 2019

From cancer(11) to epilepsy(12), there seems to be very little that cannabis cannot help with. Endocannabinoids and epilepsy - Science Direct. Please email support@strainconnect.com or try us on social media. Consult with a physician before use if you have a serious medical condition or use prescription medications.

Hemp 57

Hemp CBD Cannabinoids Sativa 57

NORML

AUGUST 26, 2019

These were moms and dads and grandparents of children [with intractable epilepsy] who were using medical cannabis oils. As in, no to anyone who wasn’t an epilepsy patient.]. The 2017 expansion of Virginia’s medical marijuana law got rid of qualifying conditions. It removed qualifying conditions altogether.

Marijuana 210

Marijuana Legalization Programs Oil 210